Psychiatric patients who excreted larger amounts of urinary free
dopamine before treatment were significantly more likely than patients
excreting smaller amounts to develop parkinsonian side effects during
moderate-dose trifluoperazine therapy. If this finding is replicated,
urinary free dopamine determinations could prove valuable in indicating
which patients should receive those antipsychotic drugs least likely to
produce extrapyramidal side effects.